Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods

Journal of Ocular Biology, Diseases, and Informatics

Volumn 3, Issue 2, 2010, Pages 64-72

  Barathi, Subramanian ^a   Charanya, Muralidaran ^b   Muthukumaran, Shivashanmugam ^b   Angayarkanni, Narayanasamy ^a   Umashankar, Vetrivel ^b  

^a VISION RESEARCH FOUNDATION   (India)

^b SANKARA NETHRALAYA   (India)

Author keywords

Docking; HCTL; Ligands; Modeling; PON2

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLESTERASE; GLUCONOLACTONASE; HOMOCYSTEINE THIOLACTONE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN; IMAGE ANALYSIS; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN INTERACTION; SEQUENCE HOMOLOGY; THREE DIMENSIONAL IMAGING;

MAMMALIA;

EID: 79955864004     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-011-9057-7     Document Type: Article

References (46)

1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-90. (Pubitemid 28198486)
2. Domagala TB, Lacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-Grand, France). 2006;52:4-10. (Pubitemid 46683309)
3. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J. 2008;22:4044-54.
4. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-80. (Pubitemid 32323376)
5. Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ, et al. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim Biophys Acta. 2004;1702:67-77. (Pubitemid 39265470)
6. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by highdensity lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-35. (Pubitemid 24035640)
7. Seo D, Goldschmidt-Clermont P. The paraoxonase gene family and atherosclerosis. Curr Atheroscler Rep. 2009;11:182-7.
8. NowakM,Wielkoszynski T, Marek B, Kos-Kudla B, Swietochowska E, Sieminska L, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med. 2009;10:185-92.
9. Angayarkanni N, Barathi S, Seethalakshmi T, Punitham R, Sivaramakrishna R, Suganeswari G, et al. Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Eye (London, England). 2008;22:969-74.
10. Ates O, Azizi S, Alp HH, Kiziltunc A, Beydemir S, Cinici E, et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med. 2009;217:17-22.
11. Tavori H, Khatib S, Aviram M, Vaya J. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg Med Chem. 2008;16:7504-9.
12. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedebergs Arch Pharmacol. 2004;369:78-88. (Pubitemid 38161225)
13. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44:6371-82. (Pubitemid 40570731)
14. The Universal Protein Resource (UniProt) 2009. Nucleic Acids Research. 2009;37:D169-74.
15. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403-10.
16. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11:412-9. (Pubitemid 38568944)
17. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-42. (Pubitemid 30047768)
18. Fiser A, Sali A. Modeller: generation and refinement of homologybased protein structure models.Methods Enzymol. 2003;374:461-91. (Pubitemid 37531821)
19. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003;31:3497-500. (Pubitemid 37442184)
20. Horke S, Witte I, Wilgenbus P, Altenhofer S, Kruger M, Li H, et al. Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Biochem J. 2008;416:395-405.
21. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815. (Pubitemid 24007801)
22. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8:477-86. (Pubitemid 126706801)
23. Wallner B, Elofsson A. Can correct protein models be identified? Protein Sci. 2003;12:1073-86. (Pubitemid 36505441)
24. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37:W623-33.
25. Thompson MA ArgusLab 4.0.1.
26. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-62. (Pubitemid 128590223)
27. Gowthaman U, Jayakanthan M, Sundar D. Molecular docking studies of dithionitrobenzoic acid and its related compounds to protein disulfide isomerase: computational screening of inhibitors to HIV-1 entry. BMC Bioinformatics. 2008;9 Suppl 12:S14.
28. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 2003;24:1999-2012.
29. Talley TT, Harel M, Hibbs RE, Radic Z, Tomizawa M, Casida JE, et al. Atomic interactions of neonicotinoid agonists with AChBP: molecular recognition of the distinctive electronegative pharmacophore. Proc Natl Acad Sci USA. 2008;105:7606-11. (Pubitemid 351830065)
30. DeLano WL (2002) The PyMOL molecular graphics system. In eds. Palo Alto, CA, USA: Delano Scientific.
31. Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng. 1998;11:739-47. (Pubitemid 28434482)
32. Cristobal S, Zemla A, Fischer D, Rychlewski L, Elofsson A. A study of quality measures for protein threading models. BMC Bioinform. 2001;2:5.
33. Hu X, Jiang X, Lenz DE, Cerasoli DM, Wallqvist A. In silico analyses of substrate interactions with human serum paraoxonase 1. Proteins. 2009;75:486-98.
34. Aydemir O, Turkcuoglu P, Guler M, Celiker U, Ustundag B, Yilmaz T, et al. Plasma and vitreous homocysteine concentrations in patients with proliferative diabetic retinopathy. Retina (Philadelphia, Pa). 2008;28:741-3. (Pubitemid 351655128)
35. Kazemi MB, Eshraghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology. 2006;57:9-14.
36. Coral K, Angayarkanni N, Gomathy N, Bharathselvi M, Pukhraj R, Rupak R. Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Investig Ophthalmol Vis Sci. 2009;50:3607-12.
37. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007;67:358-65. (Pubitemid 46894800)
38. Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr. 2009;45:278-84.
39. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87:45-51. (Pubitemid 30456934)
40. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cellmediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276:44444-9.
41. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med. 2004;37:1304-16. (Pubitemid 39349234)
42. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-8. (Pubitemid 27329844)
43. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem. 2006;281:29491-500. (Pubitemid 44536957)
44. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab. 2006;89:368-73. (Pubitemid 44767734)
45. Rosenblat M, Hayek T, Hussein K, Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004;24:175-80. (Pubitemid 38082430)
46. Fortunato G, Di Taranto MD, Bracale UM, Del Guercio L, Carbone F, Mazzaccara C, et al. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:594-600.